Work

ASC-directed nanobodies reduce inflammasome signaling and improve outcome after experimental ischemic stroke

Year: 2026
Type: preprint
Abstract: Background: Inflammasome activation contributes to ischemic brain injury, but therapeutic efforts have focused almost exclusively on individual upstream sensors such as NLR family pyrin domain-containing 3 (NLRP3). Because the inflammatory landscape shifts as persistent vessel occlusion gives way to reperfusion, inhibiting one sensor may protect incompletely. Methods: We targeted apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), the adaptor shared by multiple canonical inflammasomes, using a camelid-derived single-domain antibody (nanobody), VHH(mASC), in two complementary mouse models of ischemic stroke: permanent middle cerebral artery occlusion without reperfusion, and transient occlusion followed by reperfusion. Results: Applied before ischemia, during persistent occlusion, or immediately after reperfusion, VHH(mASC) reduced infarct volume by up to 61% and improved neurological function in every paradigm. Fluorescently labeled nanobody was enriched within ischemic brain tissue, and treatment lowered cerebral ASC abundance. ASC-positive neutrophils predominated during occlusion, whereas ASC-positive neurons and microglia were most abundant at the later time point afterreperfusion. Treatment attenuated signaling associated with NLRP3 and with absent in melanoma 2 (AIM2), and reduced caspase-1 activation, interleukin-1β maturation and gasdermin D (GSDMD) cleavage. Conclusions: ASC-directed nanobodies limit inflammasome signaling and improve outcome in acute ischemic stroke whether or not the occluded vessel is reopened, establishing adaptor-level inhibition as a strategy distinct from targeting individual sensors.
Language: English
Open Access status: green
OpenAlex ID: W7236841537
Cites: 37
Cited by:
Related to: 10